Breast Cancer Recurrence by Subtype in a Diverse, Contemporary Cohort of Young Women
Authors:
- 13 April 2023
- journal article
- conference paper
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 237 (1) , 13-23
Abstract
BACKGROUND: Young breast cancer (YBC) patients are a unique subpopulation that are often underrepresented in randomized clinical trials. Furthermore, large national cancer databases lack detailed information on recurrence, a meaningful oncologic outcome for young patients. STUDY DESIGN: A retrospective review of YBC patients (age 40 years or younger) with stage I to III breast cancer diagnosed from 2008 to 2018 was performed. Information on clinicopathologic characteristics, demographics, and outcomes was obtained from the electronic health record and chart review. Chi-square and Fisher’s exact tests were used for comparisons of categorical variables and parametric and nonparametric tests for continuous variables. RESULTS: The cohort included 1,431 women with a median follow-up of 4.8 years (range 0.3 to 12.9 years). The median age was 37 years (interquartile range 34 to 39). The study population included 598 (41.8%) White, 112 (7.8%) Black, 420 (29.4%) Asian/Pacific Islander, 281 (19.6%) Hispanic, and 20 (1.4%) “other” race/ethnicity patients. Tumor subtype was as follows: [1] hormone receptor (HR)+/human epidermal growth factor 2 (HER2–), grade (G) 1 to 2 = 541 (37.8%); [2] HR+/HER2–, G3 = 268 (18.7%); [3] HR+/HER2+ = 262 (18.3%); [4] HR–/HER2+ = 101 (7.1%); [5] HR–/HER2– = 259 (18.1%). The majority (64.2%) presented with stage II/III disease. There were 230 (16.1%) recurrences during follow-up; 74.8% were distant. Locoregional-only recurrence was seen in 17 of 463 (3.7%) patients who underwent breast conservation vs 41 of 968 (4.2%) patients undergoing mastectomy (p < 0.001). Recurrence varied by tumor subtype: [1] HR+/HER2–, G1 to 2 (14.0%); [2] HR+/HER2–, G3 (20.9%); [3] HR+/HER2+ (11.1%); [4] HR–/HER2+ (22.8%); [5] HR–/HER2– (17.8%) (p = 0.005). CONCLUSIONS: In this large, diverse YBC cohort, recurrences were most frequent among HR+/HER2–, G3, or HR–/HER2+ invasive tumors; most were distant. There were numerically similar locoregional-only recurrences after breast conservation vs mastectomy. Additional research is needed to identify predictors of recurrence.Keywords
This publication has 27 references indexed in Scilit:
- Second international consensus guidelines for breast cancer in young women (BCY2)The Breast, 2016
- The Economics of Breast Cancer in Younger Women in the U.S.American Journal of Preventive Medicine, 2016
- Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment FactorsJournal of Clinical Oncology, 2015
- Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trialsBreast Cancer Research and Treatment, 2015
- Overall survival according to type of surgery in young (≤40 years) early breast cancer patients: A systematic meta-analysis comparing breast-conserving surgery versus mastectomyThe Breast, 2015
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Cancer Recurrence: An Important but Missing Variable in National Cancer RegistriesAnnals of Surgical Oncology, 2014
- Post‐treatment regret among young breast cancer survivorsPsycho-Oncology, 2011
- Elevated Breast Cancer Mortality in Women Younger than Age 40 Years Compared with Older Women Is Attributed to Poorer Survival in Early-Stage DiseaseJournal of the American College of Surgeons, 2009
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001